Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects
Abstract
The overall objective is to provide proof-of-principle that recombinant human relaxin (rhRLX) administration will accelerate bone healing in a calvarial defect model in mice by promoting angiogenesis/vasculogenesis and osteogenesis, at least in part through incorporation of bone marrow-derived angio- and osteogenic progenitor cells into the lesion. Results from the third study conducted during this reporting period demonstrated: reproducible implementation of uniform cranial lesions of ~3.0 mm diameter and circulating concentrations of relaxin of 4.9 + 1.3 ng/ml ng/ml. However, after 10-12 days of healing, the lesion closure was comparable in the relaxin- and vehicle-treated mice (~70% each). Consistent with this finding is that there were also no significant differences in bone volume, bone/tissue volume (%) or bone and tissues mineralization densities (g/cm3). Ina parallel study, we applied relaxin locally in collagen scaffolding (1.0 g/scaffold); however, again, the lesion closure was comparable in the relaxin- and vehicle-treated mice (~80%) each. Consistent with this finding again is that there were also no significant differences in bone volume, bone/tissue volume (%) or bone and tissues mineralization densities (g/cm3). In these 2protocols we also utilized older mice of ~13-14 months of age, the idea being that the relative impairment of bone healing dueto age may be more amenable to improvement by relaxin.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2018
- Accession Number
- AD1094296
Entities
People
- Kirk P Conrad
Organizations
- University of Florida